• A Wildly Underappreciated Point: Overpaying for Infusions Means Overpaying for Stop-Loss Coverage, With Jake Velie and Keith Hartman, RPh
    Sep 23 2026
    The Hidden Link Between Expensive Infusions and Rising Stop-Loss Renewal Premiums. Episode 530. When an infusion claim lands on a self-insured plan's high-cost claims report, it's tempting to treat the price tag as fixed — but the exact same infusion drug can cost 10 times more depending on where a member receives it, and every expensive claim that breaches a stop-loss attachment point can push next year's premium higher or get that member's claim lasered off coverage entirely. In this episode, Stacey Richter talks with Jake Velie, founder, chairman, and CEO of National Integrative Health (NIH), and Keith Hartman, RPh, NIH's chief strategy officer, about the direct — not dotted — line between overpaying for infusions and overpaying for stop-loss coverage, and the four pillars plan sponsors need to actually pull off site-of-care optimization. WHAT YOU'LL LEARN ✅ Why there's a direct, not dotted, line between expensive infusion claims and rising stop-loss renewal premiums — and how breaching an attachment point can get a claim lasered off coverage ✅ How the opacity of J-codes and Q-codes on the medical benefit hides how much margin is built into an infusion's billed cost, unlike the more visible pharmacy-benefit claims data ✅ Why the exact same infusion drug can cost 10 times more depending on where a member receives it ✅ The four pillars of a real site-of-care optimization program: deep clinical oversight, proactive pre-cert intervention, plan design and financial incentives, and member/influencer engagement ✅ Why a vague "denied" fax in the pre-cert process leaves prescribing clinicians in the dark and can sabotage a site-of-care redirect before it starts ✅ How home infusion can be used as a site-of-care option even when an anticompetitive hospital contract otherwise restricts steering WHY THIS MATTERS Stop-loss coverage is usually a self-insured plan's single biggest expense, yet Stacey Richter points out that the typical reaction to an expensive infusion claim is to treat it like an unalterable fate. The same infusion can cost 10 times more depending on where a member gets it, and every claim that breaches a stop-loss attachment point pushes premiums higher or risks getting the claim excluded from coverage. As medical and pharmacy trend keeps climbing, knowing how to steer members toward lower-cost, clinically appropriate sites of care is becoming a core skill for plan sponsors — not knowing how is turning into a problematic knowledge gap. MENTIONED IN THIS EPISODE EP529 with Eric Bricker, MD: Apple Podcasts | Spotify | Other Apps EP370 with Erik Davis and Autumn Yongchu: Apple Podcasts | Spotify | Other Apps EP468 with Matt McQuide: Apple Podcasts | Spotify | Other Apps Website: National Integrative Health EP501 with Ivana Krajcinovic, PhD: Apple Podcasts | Spotify | Other Apps EP508 with Lee Lewis: Apple Podcasts | Spotify | Other Apps EP480 with Kimberly Carleson: Apple Podcasts | Spotify | Other Apps EP523 with Suhas Gondi, MD, MBA: Apple Podcasts | Spotify | Other Apps EP472 with Eric Bricker, MD: Apple Podcasts | Spotify | Other Apps === LINKS === 🔗 Show Notes with all mentioned links: Show Notes ✉️ Enjoy this podcast? Subscribe to the free weekly newsletter 🫙 Support the podcast with a small donation to the Tip Jar 🎤 Follow us on Apple Podcasts 🎤 Follow us on Spotify 📺 Subscribe to our YouTube channel === CONNECT WITH THE RHV TEAM === ✭ LinkedIn ✭ Threads ✭ Bluesky ✭ X 00:00 Introduction to this episode. 02:42 An overview of today's conversation. 05:50 The critical pillars plan sponsors underestimate. 07:44 Today's conversation with Keith and Jake. 10:08 Connecting the dots between infusion therapy costs and stop-loss coverage. 13:44 Why stop-loss carriers are starting cost-containment initiatives themselves. 17:36 The things many plans miss. 18:40 Why some plans miss or underestimate extensive clinical capabilities. 20:39 What does "good" look like, relative to a clinical team? 23:10 What do plan sponsors need to ensure further care fragmentation? 27:05 Why plan design and member financial alignment are so important. 29:44 Why is it important for plan sponsors to have a member and influencer engagement engine? 32:58 What about anti-competitive contracts and ASO resistance? 35:15 What National Integrative Health does. 36:22 Where you can go to learn more about National Integrative Health.
    Show More Show Less
    38 mins
  • Slaying the Three-Headed Monster of Health Plan Networks, With Evan Anderson
    Sep 30 2026
    Discount Illusions, Billing Errors, and Site-of-Care Markups: A Carrier Network Primer for Employers with Evan Anderson of Handl Health. Episode 531. Whatever the plan was at the very beginning, the big status quo carrier networks have evolved into what Stacey Richter calls a three-headed monster: the contractual illusion of discounts, payment integrity nobody with skin in the game is allowed to check, and wild site-of-care price swings inside the very same network. Stacey talks with Evan Anderson of Handl Health, where he works on product strategy, general strategy, and operations, about how fee-for-service networks got here and what self-insured employers, brokers, and TPAs can do around the edges right now. Consider it a primer — a survey of the general map of the landscape, with breadcrumbs to many past episodes for anyone ready to take a deep dive. WHAT YOU'LL LEARN ✅ Why a discount off a chargemaster price is "an optical illusion" — including the 2023 Health Affairs finding that at roughly half of hospitals, the discounted cash price is lower than the insurer-negotiated rate ✅ How old mainframe adjudication systems, obtuse contracts, and double-digit billing error rates make payment integrity nearly impossible to verify — because where there's mystery, there's margin ✅ How site-of-care differentials drive runaway spend, from hospital multipliers as high as 13X to $135 vs. $13,560 for the exact same infusion drug — both in-network ✅ Why switching carrier networks, even with your own claims file and transparency data, is a shrinking lever as prices regress toward the mean ✅ Three around-the-edges moves: direct contracting for advanced primary care and Centers of Excellence, steerage and tiering that include site-of-care tiers, and bundled episodes of care aggregated into alternative health plans ✅ How the broker/EBC role is shifting from network shopper to plan orchestrator WHY THIS MATTERS These networks are, lest we forget, built on a fee-for-service model that structurally aligns incentives in ways that are a lot of times misaligned with members and plan sponsors. As Evan puts it, cut one head off and the body grows it back — that body being decades of opacity (gag clauses were only banned by the CAA in 2021) and intermediaries paid in ways indifferent or positively correlated to higher spend. For plan sponsors facing extreme increases, knowing the real price, the quality, and what was actually billed is how you start chipping away at the status quo. MENTIONED IN THIS EPISODE EP505 with Ahilan Sivaganesan, MD: Apple Podcasts | Spotify | Other Apps EP434 with Benjamin Schwartz, MD, MBA: Apple Podcasts | Spotify | Other Apps Website: Handl Health Handl Health on LinkedIn Evan Anderson on LinkedIn Article: Katy Talento, ND, ScM, on a post-network world LinkedIn Post by Mark Cuban LinkedIn Post by Craig Gottwals Study: Health Affairs, hospital cash prices vs. negotiated prices EP482 with Preston Alexander: Apple Podcasts | Spotify | Other Apps EP480 with Kimberly Carleson: Apple Podcasts | Spotify | Other Apps EP521 with Andrew Tsang: Apple Podcasts | Spotify | Other Apps Article: Jim Jusko, JD, on healthcare provider networks (Medical Economics) EP529 with Eric Bricker, MD: Apple Podcasts | Spotify | Other Apps EP501 with Ivana Krajcinovic, PhD: Apple Podcasts | Spotify | Other Apps EP472 with Eric Bricker, MD: Apple Podcasts | Spotify | Other Apps EP398 with Jacob Asher, MD: Apple Podcasts | Spotify | Other Apps LinkedIn Post by Mike Hopkins EP528 with Yashaswini Singh, PhD: Apple Podcasts | Spotify | Other Apps LinkedIn Comment by Lori Smith Guliano LinkedIn Comment by Patrick Nelli EP509 with Patrick Nelli: Apple Podcasts | Spotify | Other Apps EP504 with Ryan Jacobs: Apple Podcasts | Spotify | Other Apps EP530 with Jake Velie and Keith Hartman, RPh: Apple Podcasts | Spotify | Other Apps EP523 with Suhas Gondi, MD, MBA: Apple Podcasts | Spotify | Other Apps EP503 with Ryan Wells; Leo Spector, MD, MBA; and Adam Stavisky: Apple Podcasts | Spotify | Other Apps EP294 with Steve Schutzer, MD: Apple Podcasts | Spotify | Other Apps === LINKS === 🔗 Show Notes with all mentioned links ✉️ Enjoy this podcast? Subscribe to the free weekly newsletter 🫙 Support the podcast with a small donation to the Tip Jar 🎤 Follow us on Apple Podcasts 🎤 Follow us on Spotify 📺 Subscribe to our YouTube channel === CONNECT WITH THE RHV TEAM === ✭ LinkedIn ✭ Threads ✭ Bluesky ✭ X 00:00 Introduction to this episode. 02:21 An overview of today's conversation. 06:31 The conversation with Evan Anderson. 06:40 What is a network? 08:15 The reality of contracts and care networks. 13:19 The contractual illusion of discounts. 21:17 What does a good solution look like right now? 24:35 How incentivizing providers can open opportunities. 26:44 How COE and steerage architecture plays into this. 34:02 The different role of the broker and EBC in this ...
    Show More Show Less
    38 mins
  • Level Funding Is Self-funding: 5 Avoidable Contract Risks, With Frank Pennachio
    Oct 14 2026
    Level-Funded Health Plan Risks: ERISA Contract Traps, Stop-Loss Gaps, and Surplus Fine Print. Episode 533. An employer with a fully insured plan told Stacey Richter his renewal this year was 69% — his broker negotiated it down to 50%, which she's not sure she'd classify as a victory. Level funding looks like a lifesaver in that spot, but as Frank Pennachio, author of The Silent Danger and a health insurance veteran with nearly 40 years of experience, explains, level funding is self-funding, with all the fiduciary risk that comes with it. Frank walks through five avoidable contract risks that level-funded plan sponsors fall into regularly, from embedded ERISA violations to stop-loss misalignment to surplus fine print. WHAT YOU'LL LEARN ✅ Why level funding is self-funding — it feels like a fully insured plan because of the flat monthly payment, but the plan sponsor carries the risks and benefits of self-funding, including fiduciary responsibility ✅ How third-party administrator (TPA) and administrative services only (ASO) agreements can embed ERISA violations the moment they're signed, and why ERISA allows personal assets to be exposed ✅ How stop-loss misalignment leaves the plan sponsor on the hook when plan promises, like eligibility for employees on approved leave, aren't reimbursed under the stop-loss contract ✅ The surplus fine print: incurred but not reported (IBNR) factors, service fees Frank has seen as high as 30%, and surplus returned as an invoice credit instead of a check ✅ Why claims data access promised up front can get signed away, and why fiduciaries must pay prudent fees — like a $50,000 charge to reprice one hospital bill ✅ Four action items: never sign a contract as is, educate the plan sponsor team, run a legit RFP, and pick a broker or EBC with experience and financial alignment WHY THIS MATTERS With renewals like 69% and 50%, there's a lot of desperation out there for a lifesaver, and level funding is being sold as one. But as Frank Pennachio quotes Thomas Sowell, "There are no solutions, there are only trade-offs," and the goal is for plan sponsors to pick the trade-offs they want rather than desperate ones. The cost increases will sting, Frank says, and they won't likely bankrupt most companies, but the risks you unknowingly assume could. MENTIONED IN THIS EPISODE Website: The Silent Danger, Frank Pennachio's book Website: The Silent Danger courses from Frank Pennachio EP478 with Andreas Mang and Jon Camire (Part 1): Apple Podcasts | Spotify | Other Apps EP479 with Andreas Mang and Jon Camire (Part 2): Apple Podcasts | Spotify | Other Apps LinkedIn Post by Kimberly Carleson LinkedIn Post by David Goldfarb on stop-loss cost trends EP512 with Doug Aldeen: Apple Podcasts | Spotify | Other Apps EP457 with Cynthia Fisher: Apple Podcasts | Spotify | Other Apps Study: Survey by Kaiser Family Foundation EP453 with Claire Brockbank: Apple Podcasts | Spotify | Other Apps EP433 with Justin Leader: Apple Podcasts | Spotify | Other Apps === LINKS === 🔗 Show Notes with all mentioned links ✉️ Enjoy this podcast? Subscribe to the free weekly newsletter 🫙 Support the podcast with a small donation to the Tip Jar 🎤 Follow us on Apple Podcasts 🎤 Follow us on Spotify 📺 Subscribe to our YouTube channel === CONNECT WITH THE RHV TEAM === ✭ LinkedIn ✭ Threads ✭ Bluesky 00:00 Introduction to this episode. 03:37 An overview of today's conversation. 04:57 What level funding is. 06:20 Why level funding is having an explosion in popularity. 08:03 What does an employer need to take into account when considering level funding? 09:36 The first risk of level funding. 12:24 The second risk of level funding. 15:01 The third risk of level funding. 19:45 The fourth risk of level funding. 21:46 The fifth risk of level funding. 24:41 Actionable strategies when considering level funding. 33:30 A summary of advice for level funding.
    Show More Show Less
    37 mins
  • Why Avoidable ER Visits Aren't the Real Cost Problem: Revisiting Our Interview With HHS Nominee Chris Klomp
    Oct 7 2026
    Emergency Department High Utilizers and Real-Time Care Coordination, With Chris Klomp (Episode 532) Today we are dipping into the archives for an essential replay from 2016, one decade ago, featuring Chris Klomp back when he served as CEO of Collective Medical, and now nominated to serve as deputy secretary of the Department of Health and Human Services (HHS), a nearly $2 trillion federal health apparatus. In this conversation, Klomp explains why emergency medicine is only 2 to 4% of total U.S. healthcare cost, so avoidable ED spend can't be more than about 0.8 to 0.9% of total spend, and why the emergency department is still the natural choke point for finding complex, high-risk patients. Listening back is a rare, candid preview of the operational philosophy which may now shape Chris Klomp's view on health policy. WHAT YOU'LL LEARN ✅ Why Klomp said in 2016 that emergency medicine is only 2 to 4% of total U.S. healthcare cost, versus about 6% for plan sponsors now ✅ How the ED works as a "clearinghouse" for physical, mental, behavioral, and social complexity, and why the goal is the right care setting, not stopping the visit (EMTALA) ✅ How a Pacific Northwest clinical group used real-time data and coordinated care plans to cut hospital readmission rates by close to 40% ✅ Klomp's four building blocks: real-time data (starting with an ADT feed, since claims data runs 90 to 180 days late), risk analytics, communication inside the EHR workflow, and community-wide collaboration ✅ How whole-person care took "Ron" from 23 ED visits in a month across seven hospitals to 3 at peak, and why 78% of ED high utilizers have physical, mental, and behavioral health comorbidities WHY THIS MATTERS With the nomination of Chris Klomp to serve as deputy secretary of HHS, all eyes are kind of on how he plans to manage a nearly $2 trillion federal health apparatus. The emergency department is a critical choke point through which complex, often high-risk patients inevitably pass. Not dealing effectively with these larger community issues costs everyone more than dealing with them effectively would cost, and if the country had done more of what Klomp describes ten years ago, it makes you wonder how things would be different now. MENTIONED IN THIS EPISODE EP467 with Stacey Richter: Apple Podcasts | Spotify | Other Apps EP495 with Mick Connors, MD: Apple Podcasts | Spotify | Other Apps EP464 with Al Lewis: Apple Podcasts | Spotify | Other Apps Study: Research from Peter Smulowitz, MD, MPH; Leah Honigman, MD; and Bruce Landon, MD, MBA EP322 with Monica Lypson, MD, MHPE: Apple Podcasts | Spotify | Other Apps EP473 with Kenny Cole, MD: Apple Podcasts | Spotify EP391 with Scott Conard, MD: Apple Podcasts | Spotify | Other Apps === LINKS === 🔗 Show Notes with all the mentioned links and article: Show Notes ✉️ Enjoy this podcast? Subscribe to the free weekly newsletter 🫙 Support the podcast with a small donation to the Tip Jar 🎤 Follow us on Apple Podcasts 🎤 Follow us on Spotify 📺 Subscribe to our YouTube channel === CONNECT WITH THE RHV TEAM === ✭ LinkedIn ✭ Threads ✭ Bluesky ✭ X 00:00 Introduction to this episode. 04:38 Reducing wasteful spend in healthcare. 05:37 The percentage of total healthcare costs that goes to emergency medical spend in the U.S. 07:09 Why ED spending is low-hanging fruit. 08:17 How EDs operate as choke points. 09:14 Impacting what happens in the emergency department. 17:34 What happens when a patient enters the ED. 20:57 Why it's important to have data available to everyone who might touch the patient. 24:45 The need-to-know when it comes to managing data. 28:01 Thinking about risk and imminent readmission. 30:01 Collaboration in a care plan to reduce wasteful spend. 30:53 The right data, risk analytics, communication, and community-wide collaboration. 31:11 How social determinants affect wasteful spend in the ED.
    Show More Show Less
    37 mins
  • EP534: The One Question to Test if a TPA Is Actually Independent, With Kimberly Carleson
    Oct 21 2026
    Here's a question I have heard more than once: What is a practical, speedy way to assess whether a TPA (third-party administrator) is truly independent and willing to protect the plan's interests, this plan sponsor's interests, versus being captive to, for example, network contracts or carrier relationships or other conflicts of interest? What's an easy tell that can give you an answer fast? For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. After being posed this question, I knew the perfect person to call to get an answer; and that perfect person would be Kimberly Carleson from US Beacon, the CEO of US Beacon. What You'll Learn ✅ The one question that quickly exposes whether a TPA is truly independent ✅ Why a TPA answering "We have network contracts that restrict that" is a red flag—it means they are working for the network, not the plan ✅ What a TPA should hand over without hesitation when a plan sponsor asks for an independent claims audit ✅ How blocking language in TPA and network contracts—restrictions on accessing data or contacting providers—can stop a plan from independently reviewing its own claims and payments ✅ How an "independent" TPA can still be beholden to a network, renting that network and acting the same way any BUCA would ✅ Why labels like "transparent" and "independent" aren't proof, and why due diligence matters: talk is cheap Why This Matters Plan sponsors who go self-funded want to do their own thing and bring in their own vendors, not end up "self-funded in name only," as Jonathan Baran calls it. But irrespective of what a partner calls itself, it's still really important to validate what you hear. A TPA's willingness to let you bring in your own auditor—with access to the data and no blocking language in its network contracts—is a fast way to find out whether it works for the plan or for the network. And as Kimberly says, if you can't bring in who you want to bring in, there's something they don't want you to see. And with that, here is my Ask Me Anything with Kimberly Carleson. Also mentioned in this episode are US Beacon, Claire Brockbank, Jonathan Baran, and Arielle Bose. For a list of healthcare industry acronyms and terms that may be unfamiliar to you, click here. You can learn more at us-beacon.com and by following Kimberly on LinkedIn. Kimberly Carleson is a nationally respected healthcare executive and patient advocate with more than 15 years of experience serving patients, self-funded health plans, state governments, public entities, small businesses, and Fortune 500 companies in the areas of reimbursement integrity, regulatory compliance, and fiduciary governance. As CEO of US Beacon, Kimberly leads one of the nation's most established independent medical and pharmacy claims compliance and integrity review firms, supporting self-funded health plans, municipalities, and large employers. Her work focuses on identifying systemic overbilling, coding inaccuracies, and contractual noncompliance, delivering substantial, defensible savings while strengthening oversight and accountability. She has served as a panelist for ERIC (The ERISA Industry Committee) and the National Auditors Association, and her work has been referenced in federal policy discussions related to healthcare oversight and fiduciary accountability. 00:00 Introduction to this episode. 01:19 The conversation with Kimberly Carleson. 01:50 EP518 with Claire Brockbank. 02:24 The one question to tell if a TPA is independent. 03:30 Breaking down the thought process behind this question. 05:59 How an independent TPA can still be beholden to a network. 06:48 Why it's so important to do due diligence. Recent past interviews: Click a guest's name for their latest RHV episode! Frank Pennachio, Chris Klomp, Evan Anderson, Jake Velie and Keith Hartman, Dr Eric Bricker, Yashaswini Singh, Mark Cuban and Cora Opsahl
    Show More Show Less
    9 mins
  • EP535: When Patient Experience Means Parking and Pianos, Plan Sponsors Pay for Hotels, Not Outcomes—What to Measure Instead, With Robyn Leone
    Oct 28 2026
    On episode 532 a few weeks ago, Chris Klomp from HHS was talking about ER (emergency room) usage as a signal, not just a statistic. If too many folks show up in the ER, consider this a signal that there's something missing. It means a patient who doesn't have access to primary care, or maybe specialist care, or maybe doesn't know where to go to get the care or is too sick to figure this out. Or maybe there's onerous prior auth requirements or long delays that you can avoid if you just go to the ER and/or a clinical organization is requiring up-front payment that a patient doesn't have on hand to make an appointment. Right? For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. All of these things are things that are blazing red flags that patients, who are also members, are lost. If you consider a lost patient as a patient having a wildly poor patient experience, then it becomes, I don't know, kind of inarguable that true patient experience in healthcare is not, like, a superficial amenity such as pianos in the lobby or espresso machines. Patient experience is, instead, a direct operational consequence of the architecture underpinning any given patient journey—or lack of architecture underpinning any given patient journey, as the case may be. And, by the way, the irony of talking right now about underlying architecture for the patient journey being the solve for what patient experience really should be … yeah, this irony is not lost on me. We currently have a healthcare industry slightly obsessed with architecture, but I'm talking the real estate kind with lots of marble and waterfalls and fancy art, of course. But yeah, instead of the real estate kind of architecture, in the show today, we concern ourselves with making sure that our patient's journey is architected, that there's true design thinking here for what we want our patient experiences to be and/or member experiences to be, because same thing. Unequivocally, without this kind of architecture, the kind that holds together a solid patient journey, we're not going to get patients (ie, members) the right diagnosis and the right treatment for that diagnosis; and we probably also won't get outcomes at an affordable price. We're just not for all the reasons that we talk about endlessly in episode after episode on this podcast. Listen to the episodes with Preston Alexander (EP482); Vivian Ho, PhD (EP466); Shane Cerone and Sam Flanders, MD (EP492); or go back and listen to the first episode with Suhas Gondi, MD, MBA (EP404) for maybe places to start. I say all this to say or, more accurately, for Robyn Leone to say coming up here, if we are talking about patient experience, this right here—getting the right diagnosis, right care, affordable price—is what the measure of patient experience really should be. I mean, otherwise, what are we even doing here? It's supposed to be a healthcare industry. But in many respects, we often measure experience in ways that don't include how easy and affordable it is to walk out having been appropriately cared for. Bottom line and key takeaway from this conversation with my guest, Robyn Leone, today: Patient experience is a function of experience architecture. Good intentions, clinician empathy, and customer service cannot overcome a bad structural design. And I say that in defense of clinicians as much as on behalf of patients and plan sponsors. True experience means organizational leadership getting architecture right to enable the right diagnosis and the right treatment at a fair and affordable price. And plan sponsors, you get what you pay for intentionally or otherwise. So, yeah. Robyn Leone talks about architecting the patient journey as building three buildings, metaphorical buildings now, that we should be constructing so that patients can make it through their encounters with the healthcare industry having received the highest-value-possible care as the default. The three buildings in your member and/or patient experience journey should be building one, access and navigation. So, this is what happens prior to anybody needing care. That's the first building. The second building houses delivery and care coordination. So, this is what happens during the care episodes. How well is the whole person treated? And then the third building is what happens after, where there should be transparent and accountable billing. And right, a lot of this will only work if a provider is working with plan sponsors who get in there and probably have direct contracts, who are deliberately paying for the patient experience that the plan sponsor wants their members to receive, and is actively involved in steering and tiering. And also, with an underline, is investing, I would say, in true measurable, accountable, advanced primary care. Robyn Leone, my guest today, is the chief experience officer over at ...
    Show More Show Less
    37 mins
  • The Sleeping Giants of Healthcare—Why Self-insured Employers and Clinicians Keep Missing Each Other, With Suhas Gondi, MD, MBA. EP523
    Aug 5 2026
    Why Self-Insured Employers and Clinicians Keep Missing Each Other, With Suhas Gondi, MD. The Sleeping Giants of Healthcare: Why Employers and Clinicians Keep Missing Each Other. Episode 523. Dr. Suhas Gondi, MD, MBA, chief medical officer at Health Strategy and an attending physician at Massachusetts General Hospital, co-wrote a New England Journal of Medicine article — "A Sleeping Giant of Health Care Affordability—Self-Insured Employers" — because most clinicians, he found, have little idea a self-insured employer, not an insurance carrier, is the one actually paying for their patients' care. Talking with Stacey Richter, Dr. Gondi argues that self-insured employers and clinicians are both "sleeping giants," each holding real power over cost and access, who rarely communicate directly — leaving patients caught in the gap. WHAT YOU'LL LEARN ✅ Why Dr. Suhas Gondi and his NEJM co-author, Zirui Song, MD, PhD, wrote for clinicians who, they found, have little sense that a self-insured employer — not the carrier name on the card — actually pays for a patient's care ✅ How a GLP-1 prescription can get denied at the pharmacy counter even after a clinician verifies coverage, because the employer has quietly moved GLP-1 coverage exclusively through a single third-party prescribing and coaching vendor ✅ Why GLP-1 spending alone can push a self-insured employer's pharmacy costs up 9% to 20% in a year, and why the roughly eight-year payback period employers are counting on assumes patients stay adherent far longer than most actually do ✅ How oncology site-of-care steering — an employer declining to pay a roughly 40% premium for infusion at a hospital-owned center instead of a physician's office — can look to the patient and oncologist like a denied cancer drug ✅ Why Dr. Gondi says EHRs like Epic are built to optimize revenue for hospital-system customers, not to surface a lower-cost site of care for patients or plan sponsors ✅ Dr. Gondi's advice for closing the gap: clinicians and employers should communicate directly, especially before a coverage change lands on patients, rather than assuming direct contracting is the only fix WHY THIS MATTERS Roughly half to 60% of the US population has commercial insurance, and nearly three-quarters of large employers self-insure that coverage — yet most clinicians have no visibility into the plan-level decisions those employers make, and most employers have no channel to explain those decisions to the doctors whose patients are affected. Both sides, Dr. Gondi says, usually believe they're doing the right thing — covering the GLP-1, covering the cancer drug — and the patient still gets lost in between. Closing that gap doesn't require full direct contracting, he argues, just employers and local provider groups actually talking to each other before a coverage change lands on a patient, not after. MENTIONED IN THIS EPISODE Study: New England Journal of Medicine article, "A Sleeping Giant of Health Care Affordability—Self-Insured Employers," by Suhas Gondi, MD, MBA, and Zirui Song, MD, PhD EP406 with Lauren Vela: Apple Podcasts | Spotify | Other Apps EP519 with Lisa Rosenbaum, MD: Apple Podcasts | Spotify | Other Apps EP509 with Patrick Nelli: Apple Podcasts | Spotify | Other Apps EP494 with Sarah Emond: Apple Podcasts | Spotify | Other Apps EP501 with Ivana Krajcinovic, PhD: Apple Podcasts | Spotify | Other Apps EP468 with Matt McQuide: Apple Podcasts | Spotify | Other Apps Article: Acquired's episode on how Epic quietly powers American healthcare === LINKS === 🔗 Show Notes with all mentioned links: Episode Page ✉️ Enjoy this podcast? Subscribe to the free weekly newsletter 🫙 Support the podcast with a small donation to the Tip Jar 📺 Subscribe to our YouTube channel 🎤 Listen on Apple Podcasts 🎤 Listen on Spotify === CONNECT WITH THE RHV TEAM === ✭ LinkedIn ✭ Threads ✭ Bluesky ✭ X 00:00 Introduction to this episode. 00:35 A big thank you. 06:22 The conversation with Dr. Suhas Gondi. 07:08 Why Dr. Suhas Gondi and his coauthor wrote their article. 09:24 Why the affordability of care and the decisions self-employers are making about coverage matter to clinicians. 12:12 What the term "sleeping giants" implies and how that reflects the reality of healthcare. 14:31 A case study. 21:24 How the patient can still get lost even when both the employer and clinician think they're doing the right thing. 22:52 An example from the oncology space. 28:47 Dr. Suhas Gondi's advice to clinicians. 30:55 The communication gap between clinicians and employers. 33:30 Why the presence of middlemen should not prevent communication between clinicians and employers.
    Show More Show Less
    35 mins
  • Mark Cuban and Cora Opsahl: The Truth About Pass-Through PBM Contracts and Generic Compliance Ratios
    Aug 26 2026
    How Discount Theater and Generic Compliance Ratios Quietly Overcharge Patients and Employers. Episode 526. Mark Cuban, co-founder of Mark Cuban Cost Plus Drug Company, and Cora Opsahl, managing director of Peterson Health Analytics and former director of the 32BJ Health Fund, join Stacey Richter for an outtake from their conversation last fall (EP488) on the operational mechanics of the pharmacy supply chain. They trace how a generic compliance ratio—typically requiring pharmacies to buy at least 92% of their generics from a single primary wholesaler—pushes independent pharmacies into paying a premium that gets passed straight to patients, and how so-called pass-through PBM contracts can pay pharmacies using one pricing formula while billing employers using an entirely different one. Along the way, they walk through the classic generic imatinib example—a drug Cost Plus Drugs sells for $25 a month that a traditional PBM channel has billed at $9,000—to show why a discount off an inflated reference price is, as Cuban puts it, discount theater. WHAT YOU'LL LEARN ✅ Why pharmacies get locked into overpaying: wholesalers set a Generic Compliance Ratio requiring pharmacies to buy at least 92% of their generics from them or face chargebacks and fees that wipe out their margin ✅ The classic generic imatinib example: Cost Plus Drugs sells it for $25 a month, while the same drug billed through a traditional PBM channel has run $9,000 a month—a "discount" off a $27,000 branded Gleevec price that Mark Cuban calls discount theater ✅ How specialty tiers compound the problem: because generic imatinib gets classified on a specialty tier, patients can owe 25% coinsurance calculated off the inflated WAC price rather than the drug's real cost ✅ Why a "pass-through" PBM contract isn't simple math: Cora Opsahl explains that PBMs often reimburse pharmacies on an acquisition-cost-plus formula while billing employers a completely different AWP-minus formula for the same claim ✅ Why claims audits keep finding money owed back to the plan—and why employers are often restricted to auditing only a pre-approved sample of 250 claims ✅ Mark Cuban's advice for the next RFP: simply requiring that Cost Plus Drugs be included in the network is often enough on its own to get PBMs to offer better rebates and terms WHY THIS MATTERS As Stacey Richter puts it, where there's mystery, there's margin—and pharmacy pricing is thick with both. Generic compliance ratios, WAC-based specialty tiers, and pass-through contracts that pay pharmacies one number while billing employers another all point to the same underlying reality: so much of what gets called an expense in medicine is simply pricing failure. For plan sponsors and brokers heading into their next RFP, understanding these mechanics—rather than accepting a discount off an inflated reference price—is what it takes to move from passive price taker to informed decision maker. MENTIONED IN THIS EPISODE EP429 with Luke Slindee, PharmD: Apple Podcasts | Spotify | Other Apps EP488 with Mark Cuban and Cora Opsahl: Apple Podcasts | Spotify | Other Apps EP422 with Benjamin Jolley, PharmD: Apple Podcasts | Spotify | Other Apps EP465 with Chris Crawford: Apple Podcasts | Spotify | Other Apps EP486 with Stan Schwartz, MD: Apple Podcasts | Spotify | Other Apps === LINKS === 🔗 Show Notes with all mentioned links: Episode Page ✉️ Enjoy this podcast? Subscribe to the free weekly newsletter 🫙 Support the podcast with a small donation to the Tip Jar 📺 Subscribe to our YouTube channel 🎤 Listen on Apple Podcasts 🎤 Listen on Spotify === CONNECT WITH THE RHV TEAM === ✭ LinkedIn ✭ Threads ✭ Bluesky ✭ X 00:00 Introduction to this episode. 03:43 An overview of today's conversation. 05:59 Today's conversation with Mark Cuban and Cora Opsahl. 07:25 Why discounts are meaningless without knowing the absolute price. 09:29 What a generic compliance ratio does. 12:28 Thinking about the demand side for employers. 15:00 The complication of a pass-through contract. 17:48 Why too much of healthcare comes down to a negotiation.
    Show More Show Less
    20 mins